Protagonist Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PTGX research report →
Range $160 – $190
Price Chart
About the company
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders.
- CEO
- Dinesh V. Patel
- IPO
- 2016
- Employees
- 141
- HQ
- Newark, CA, US
Get TickerSpark's AI analysis on PTGX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $7.92B
- P/E
- 23.54
- Fwd P/E
- 23.43
- PEG
- -0.01
- P/S
- 14.36
- P/B
- 7.43
- EV/EBITDA
- 21.15
- Div Yield
- 0.00%
- Gross Margin
- 99.73%
- Op Margin
- 58.56%
- Net Margin
- 62.04%
- ROE
- 42.83%
- ROIC
- 28.87%
Latest fiscal year · YoY change
- Revenue
- $46.02M-89.4%
- Gross Profit
- $44.79M-89.7%
- Op Income
- $-158,127,000
- Net Income
- $-130,149,000-147.3%
- EPS
- $-2.05-145.9%
- OCF Growth
- -68.7%
- FCF Growth
- -69.3%
- 52W High
- $160.81
- 52W Low
- $77.00
- 50D MA
- $138.68
- 200D MA
- $120.13
- Beta
- 1.79
- RSI (14)
- 33
- Avg Volume
- 665.36K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Protagonist said 2020 was a transformative year, highlighting stronger rusfertide data in PV and continued progress across a broader pipeline, while revenue rose sharply from Janssen collaboration activity.· March 10, 2021
- Rusfertide showed continued clinical activity in PV, with management saying it was safe, well tolerated, and effective at keeping hematocrit below 45% across 18 patients.
- Management said the drug also reduced phlebotomy needs and appeared to reverse iron deficiency, which they framed as the key problem in current PV care.
- The company said it now has five NCEs in six clinical studies, with multiple readouts expected over the next 2 years.
- Management expects regulatory clarity on PV in the first half of 2021, but said the FDA dialogue is still ongoing.
- Janssen collaboration revenue drove the year-over-year increase in reported revenue, and Protagonist said it has at least three IL-23 candidates in its development bucket.
Protagonist reported full-year 2020 license and collaboration revenue of $28.6 million, up from $0.2 million in full-year 2019. Fourth-quarter 2020 license and collaboration revenue was $5.7 million versus $2.7 million in the same quarter of 2019. Management attributed the year-over-year increase to revenue recognition from Janssen collaboration work on PN-235 and PN-232 and to an update to the forecast of remaining services under the agreement. The transcript did not include EPS, gross margin, or other income statement metrics. Looking ahead, management said PV regulatory clarity is expected in the first half of 2021, and that updates from the open-label Phase 2 PV study would be presented at medical conferences throughout the year.
Dinesh Patel’s tone was optimistic and expansive, emphasizing that 2020 was “exceptional and transformative” because the company expanded its pipeline and advanced five NCEs across six clinical studies. He highlighted rusfertide as the most advanced program and said the Phase 2 PV data were a turning point, with the drug appearing to provide broad utility for patients whose current therapy is ineffective. He also framed the IL-23 and IBD work as part of a larger platform strategy and said the company is aiming for multiple options as more data emerge.
Don Kalkofen focused on reported revenue and the revenue recognition drivers tied to the Janssen collaboration. He said full-year 2020 license and collaboration revenue was $28.6 million, versus $0.2 million in 2019, and fourth-quarter revenue was $5.7 million versus $2.7 million a year earlier. He explained that 2019 revenue had been affected by a $9.4 million one-time cumulative adjustment from the Janssen agreement amendment, and that 2020 revenue reflected preclinical and clinical development activities for PN-235 and PN-232 plus an updated forecast of remaining services. The call did not include cash balance, burn, margin, or capital allocation details.
Most of the Q&A centered on rusfertide’s PV regulatory path and endpoint design, plus how the drug might fit in the treatment paradigm. Management said it could not give definitive FDA guidance yet, but indicated the key endpoint would likely center on keeping hematocrit below 45% over a meaningful period, with the broader issue being how the endpoint is defined and analyzed. Analysts also asked about gut-restricted versus systemic activity for PN-943 and IL-23 programs; management said Protagonist’s approach is gut-restricted, that blood receptor occupancy is a surrogate for local target engagement, and that 74% blood receptor occupancy in healthy humans serves as a guidepost for the gut-restricted approach. On PV positioning, management said rusfertide is intended for patients with too many phlebotomies and where current therapy is ineffective, rather than as a replacement for any one existing therapy.
The bull case from this call is that rusfertide continues to generate encouraging PV data, with management describing strong hematocrit control, fewer phlebotomies, and improvement in iron deficiency. The company also appears to have a broader, platform-driven pipeline with multiple shots on goal, and management expressed confidence that PV regulatory clarity will arrive in the first half of 2021.
The main risks discussed were regulatory uncertainty and dependence on further FDA alignment for the PV program, especially around endpoint design and study structure. Management also acknowledged that many questions remain open on the IL-23 programs, including how gut-restricted versus systemic approaches will translate into future indications, and that much of the collaboration revenue is tied to Janssen-related development activity rather than product sales.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 81.8%
- Shares Outstanding
- 65.27M
- Float Shares
- 53.36M
of shares held by institutions
358 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 10.73M | ▲ 426.46K |
| Farallon Capital Management, L.L.C. | 6.35M | 0 |
| Vanguard Group Inc | 5.41M | ▲ 1.16M |
| Rtw Investments, LP | 5.06M | ▲ 2.12K |
| Ubs Group AG | 3.95M | ▲ 554.01K |
| Vanguard Portfolio Management LLC | 3.67M | ▲ 39.18K |
| State Street Corp | 3.48M | ▲ 157.71K |
| Wellington Management Group Llp | 3.42M | ▼ 182.86K |
| Vanguard Capital Management LLC | 2.90M | ▲ 41.77K |
| Janus Henderson Group Ltd. | 2.89M | ▲ 241.55K |
| Invesco Ltd. | 2.84M | ▲ 496.65K |
| Johnson & Johnson | 2.45M | 0 |
Held by 505 ETFs
Biggest fund positions in PTGX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | MOLINA ARTURO MD | sell | 2,718 |
| Sep 30, 26 | Ali Asif | other | 5,312 |
| Sep 30, 26 | Ali Asif | other | 15,650 |
| Sep 30, 26 | Ali Asif | sell | 12,595 |
| Sep 30, 26 | Ali Asif | other | 28,438 |
| Sep 30, 26 | Ali Asif | other | 9,229 |
| Sep 30, 26 | Ali Asif | sell | 46,034 |
| Sep 30, 26 | Ali Asif | other | 15,650 |
| Sep 30, 26 | Ali Asif | other | 28,438 |
| Sep 30, 26 | Ali Asif | other | 9,229 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PTGX coverage
Recent articles, reports, and earnings notes.
Want a deeper read on PTGX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Protagonist Therapeutics, Inc. $PTGX Holdings Raised by Bessemer Group Inc.
defenseworld.net · Nov 18
How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 37.6%
zacks.com · Nov 16
Protagonist Therapeutics (PTGX) Q3 Earnings and Revenues Surpass Estimates
zacks.com · Nov 5
Protagonist Therapeutics (PTGX) to Report Q3 Results: Wall Street Expects Earnings Growth
zacks.com · Oct 29
Why Protagonist Therapeutics (PTGX) is a Top Momentum Stock for the Long-Term
zacks.com · Oct 29
Wall Street Analysts See a 25.34% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?
zacks.com · Oct 28
Protagonist Therapeutics: The Opt-Out That Turned A Biotech Into A Royalty Compounder
seekingalpha.com · Oct 24
Analyzing Protagonist Therapeutics (NASDAQ:PTGX) and Sarepta Therapeutics (NASDAQ:SRPT)
defenseworld.net · Oct 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
